nyse kdmn industry biotechnology founded 2009 founder samuel d. waksal headquarters 450 east 29th street new york ny 10016 united states number of locations warrendale pa and brighton ma key people harlan w. waksal md chairman and ceo mr. konstantin poukalov chief financial officer and executive vice president mr. steven n. gordon j.d. esq. executive vice president and general counsel products ribisphere number of employees 140 1 website kadmon.com kadmon corporation originally kadmon pharmaceuticals is a biopharmaceutical company based in new york city . it also has operations in warrendale pa and brighton ma . the company was founded in 2009 by samuel d. waksal 2 3 founder and former ceo of imclone systems now fully merged into eli lilly and company . waksal had served a federal prison sentence stemming from his fiduciary role as ceo in the 2001 imclone stock trading case . when released in 2009 he was barred from serving as an officer for any publicly traded company but kadmon was privately financed . 4 5 in september 2014 amid plans to take the company to an ipo harlan w. waksal brother of samuel waksal became president and chief executive officer while samuel waksal remained on with the title chief of innovation science and strategy . 6 in early 2016 sam waksal left kadmon and in june the company filed paperwork for its ipo . 7 8 on july 27 2016 the company s stock began trading on the nyse under the symbol kdmn . 9 product acquisitions edit during waksal s leadership of imclone the company was engaged in early stage research projects for 15 years before filing its first drug application . 10 kadmon however immediately began acquiring drugs further advanced either already marketed in the us or in the later stages of clinical development . 11 it acquired the warrendale pa based company three rivers pharmaceuticals and their ribasphere and topotecan products . 12 it also signed an agreement with ontario canada based valeant pharmaceuticals for their hepatitis c drugs ribavirin and taribavirin now kd024 . 13 cancer drugs xl647 10 and xl844 11 were acquired from exelixis . an inhibitor of several protein kinases xl647 kd019 entered phase ii clinical trial for certain indications of non small cell lung cancer . 14 15 and in polycystic kidney disease . 16 xl844 is an inhibitor of protein kinases chk1 and chk2 and may increase the sensitivity of cancer cells to radiation therapy . 17 in an acquisition atypical for a biotechnology company an 1800 year old chinese herbal formula was added to kadmon s portfolio . phytoceutica s phy906 kd018 is a formula of four botanical products that had long been used for the treatment of gastrointestinal distress . preclinical studies have shown it to enhance the therapeutic activity of several anticancer agents . 18 in 2014 kd018 was in a phase ii trial in combination with irinotecan in metastatic colon cancer . 19 in 2011 the company acquired rights from brighton ma based nano terra inc. 20 for their pharmacomer technology research platform and three drug candidates in clinical development . 21 these compounds include slx 2119 kd025 an inhibitor to rho kinase 2 rock2 with possible potential in fibrotic disease 22 and focal cerebral ischemia . 23 slx 4090 kd026 is a triglyceride transfer protein mtp inhibitor being explored for metabolic disorders . 24 slx 2101 kd027 is a phosphodiesterase 5 pde5 inhibitor a class of drug used in the treatment of erectile dysfunction . 25 in 2012 the rights to salirasib kd032 a ras antagonist in development for cancer therapy 26 were acquired from concordia pharmaceuticals of fort lauderdale fl . 27 it also acquired the rights from burlington ma based dyax corp. for dx 2400 28 a matrix metalloproteinase 14 mpp 14 tarageted monoclonal antibody intended to inhibit tumor blood vessel formation and metastasis . 29 as of december 2012 kadmon was developing a drug for gastric cancer 30 products edit as of 2012 kadmon produces four drugs approved by the food and drug administration in the united states ribisphere ribavirin usp tablets for the treatment of chronic hepatitis c 31 infergen interferon alfacon 1 injection for the treatment of hepatitis c 32 amphotec amphotericin b an injectable anti fungal drug 33 topotecan hydrochloride for injection approved for certain indications of small cell lung cancer and cervical cancer . 34 references edit company overview of kadmon holdings llc . bloomberg l.p. retrieved 25 september 2016 . biotechnology company overview of kadmon corporation llc . bloomberg.com . retrieved 3 december 2012 . bartiromo maria . sam waksal kadmon pharmaceuticals ceo . cnbc.com . retrieved 4 december 2012 . former imclone chief acquires drug company . the new york times . 25 october 2010 . retrieved 7 december 2012 . 2012 private financing 50mil . form d. us securities and exchange commission . retrieved 7 december 2012 . kadmon corporation announces the appointment of dr. harlan w. waksal as president . kadmon corporation announcements . kadmon corporation . retrieved 13 november 2014 . lash alex june 13 2016 . kadmon seeks ipo with unusual terms that benefit waksal debt holders . xconomy . retrieved september 25 2016 . carroll john june 10 2016 . sam waksal exited kadmon with 25m severance deal ahead of ipo . fiercebiotech . retrieved september 25 2016 . sam waksal s kadmon holdings shares open below offering price in debut . cnbc llc . retrieved 25 september 2016 . a b pollack andrew 31 october 2012 . imclone ex chief embarks on new biotech venture . the new york times . retrieved 8 december 2012 . a b fitzpatrick dimond ph.d. patricia . tales from the biotech crypt sam waksal is back in business . insight & intelligence . genetic engineering & biotechnology news . retrieved 8 december 2012 . company overview of three rivers pharmaceuticals llc . bloomberg businessweek . bloomberg.com . retrieved 8 december 2012 . ho solarina 1 november 2010 . valeant kadmon sign deals on hepatitis c drugs . thomson reuters . retrieved 8 december 2012 . chmielecki juliann ; pietanza m. catherine ; aftab dana ; shen ronglai ; zhao zhiguo ; chen xi ; hutchinson katherine ; viale agnes ; et al. 2012 . egfr mutant lung adenocarcinomas treated first line with the novel egfr inhibitor xl647 can subsequently retain moderate sensitivity to erlotinib . journal of thoracic oncology . 7 2 434 42 . doi 10.1097 jto .0 b013e31823c5aee . pmc 3261336 . pmid 22173702 . pietanza m. catherine ; gadgeel shirish m. ; dowlati afshin ; lynch thomas j. ; salgia ravi ; rowland kendrith m. ; wertheim michael s. ; price katharine a. ; et al. 2012 . phase ii study of the multitargeted tyrosine kinase inhibitor xl647 in patients with non small cell lung cancer . journal of thoracic oncology . 7 5 856 65 . doi 10.1097 jto .0 b013e31824c943f . pmid 22722787 . clinical trial number nct01559363 for a safety pharmacokinetic and dose escalation study of kd019 in subjects with autosomal dominant polycystic kidney disease at clinicaltrials.gov riesterer oliver ; matsumoto fumihiko ; wang li ; pickett jessica ; molkentine david ; giri uma ; milas luka ; raju uma 2009 . a novel chk inhibitor xl 844 increases human cancer cell radiosensitivity through promotion of mitotic catastrophe . investigational new drugs . 29 3 514 22 . doi 10.1007 s10637 009 9361 2 . pmid 20024691 . liu shwu huey ; cheng yung chi 2012 . old formula new rx the journey of phy906 as cancer adjuvant therapy . journal of ethnopharmacology . 140 3 614 23 . doi 10.1016 j.jep .2012.01.047 . pmid 22326673 . a phase ii multicenter randomized placebo controlled double blinded clinical study of kd018 as a modulator of irinotecan chemotherapy in patients with metastatic colorectal cancer . clincaltrials.gov . u.s. national institutes of health . retrieved 9 august 2014 . company overview of nano terra . bloomberg businessweek . bloomberg.com . retrieved 8 december 2012 . kadmon pharmaceuticals and nano terra announce worldwide exclusive licensing agreement for three novel product candidates . nanowerk.com . retrieved 8 december 2012 . boerma marjan ; fu qiang ; wang junru ; loose david s ; bartolozzi alessandra ; ellis james l ; mcgonigle sharon ; paradise elsa ; et al. 2008 . comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of rho kinase or atorvastatin . blood coagulation & fibrinolysis . 19 7 709 18 . doi 10.1097 mbc .0 b013e32830b2891 . pmc 2713681 . pmid 18832915 . lee j ; zheng y ; von bornstadt d ; wei y ; balcioglu a ; daneshmand a ; yalcin n ; et al. 2014 . selective rock2 inhibition in focal cerebral ischemia . . ann clin transl neurol . 1 1 2 14 . doi 10.1002 acn3 .19 . pmc 3900310 . pmid 24466563 . kim enoch ; stewart campbell ; olivier schueller ; et al. june 2011 . a small molecule inhibitor of enterocytic microsomal triglyceride transfer protein slx 4090 biochemical pharmacodynamic pharmacokinetic and safety profile . journal of pharmacology and experimental therapeutics . 337 3 775 85 . doi 10.1124 jpet .110.177527 . pmid 21406547 . retrieved 8 december 2012 . leonardi r ; alemanni m 2011 . the management of erectile dysfunction innovations and future perspectives . archivio italiano di urologia andrologia . 83 1 60 2 . pmid 21585174 . mashiach farkash e ; rak r ; elad sfadia g ; haklai r ; carmeli s ; kloog y ; wolfson hj 2012 . computer based identification of a novel limk1 2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton . oncotarget . 3 6 629 39 . pmc 3442289 . pmid 22776759 . kadmon acquires first in class ras antagonist from concordia pharmaceuticals . biospace inc. retrieved 8 december 2012 . novel mmp 14 inhibitor to be developed in multi indication oncology program . dyax corporation . retrieved 8 december 2012 . devy l. ; huang l. ; naa l. ; yanamandra n. ; pieters h. ; frans n. ; chang e. ; tao q. ; et al. 2009 . selective inhibition of matrix metalloproteinase 14 blocks tumor growth invasion and angiogenesis . cancer research . 69 4 1517 26 . doi 10.1158 0008 5472 . can 08 3255 . pmid 19208838 . targeted therapy for treatment of advanced gastric cancer . qualifying therapeutic discovery project grants for the state of new york . us department of the treasury . retrieved 8 december 2012 . ribasphere ribavirin usp tablets and capsules . kadmon.com . retrieved 8 december 2012 . infergen interferon alfacon 1 . kadmon.com . retrieved 8 december 2012 . amphotec amphotericin b injection lipid complex . u.s. national library of medicine . department of health & human services medicine . retrieved 7 december 2012 . topotecan hydrochloride injection powder for solution . u.s. national library of medicine . us department of health & human services . retrieved 7 december 2012 . retrieved from https en.wikipedia.org w index.php title kadmon corporation & oldid 743227660 categories biotechnology companies of the united statescompanies listed on the new york stock exchange navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 8 october 2016 at 16 46 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile